Donna McKay is President and Chief Executive Officer of the Breast Cancer Research Foundation (BCRF), one of the world’s leading private funders of breast cancer research. Under her leadership, BCRF supports investigators across top academic and medical institutions globally, advancing research in aggressive and metastatic breast cancers, improving risk assessment and prevention strategies, and addressing disparities in outcomes. Working closely with an independent Scientific Advisory Board and multiple governance bodies, she has reinforced BCRF’s model of rapidly funding high-impact science and strengthening international collaboration across the research continuum.
Prior to joining BCRF, McKay spent a decade as Chief Executive Officer of Physicians for Human Rights, where she led significant organisational growth, expanded global partnerships, and strengthened the use of scientific evidence in advocacy. Earlier, she held senior advancement roles at the ACLU and the U.S. Fund for UNICEF, including co-founding international advocacy networks and leading global health campaigns. Her leadership combines strategic growth, global advocacy, and a commitment to scientific rigor—positioning BCRF to translate research investment into meaningful progress for patients worldwide.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Most Influential CEOs in Oncology in 2025, and stay tuned for other special category nominations.
